AI Article Synopsis
- The study investigated the effects of rivastigmine on motor and cognitive issues in patients with Huntington's disease through a randomized controlled trial with 21 participants.
- After 8 months, 14 patients received medication while 7 were in a no-treatment group, with similar backgrounds.
- Results indicated that enhancing cholinergic transmission with rivastigmine had a modest positive impact on cognitive abilities and may slow down motor decline in HD patients.
Article Abstract
To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington's disease (HD), we carried out a prospective, open-label, randomized, controlled study. Twenty-one HD patients were enrolled: 14 were randomly sorted into medication and 7 to no-treatment groups. Clinical and demographic features were similar between groups. After 8 months, an efficacy evaluation was carried out to compare the two groups. The improvement of cholinergic transmission in HD patients seemed to have a slight effect in ameliorating cognitive performance and slowing motor deterioration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.20235 | DOI Listing |
Publication Analysis
Top Keywords
rivastigmine motor
8
motor cognitive
8
cognitive impairment
8
impairment huntington's
8
huntington's disease
8
effects rivastigmine
4
disease evaluate
4
evaluate efficacy
4
efficacy rivastigmine
4
disease carried
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!